Selective M1 receptor agonist. Induces atropine-sensitive contractions of isolated guinea pig ilea and trachea preparations (EC50 values are 3.5 and 3 μM respectively). Reverses AF64A-induced cognitive impairments in vivo.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 235.77. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.75 mM||5.66 mL||28.28 mL||56.55 mL|
|3.75 mM||1.13 mL||5.66 mL||11.31 mL|
|7.5 mM||0.57 mL||2.83 mL||5.66 mL|
|37.5 mM||0.11 mL||0.57 mL||1.13 mL|
References are publications that support the biological activity of the product.
Wanibuchi et al (1990) Pharmacological studies on novel muscarinic agonists, 1-oxa-8-azaspiro[4.5]decane derivatives, YM796 and YM954. Eur.J.Pharmacol. 187 479 PMID: 1963596
Fisher et al (1991) (+/-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease. J.Pharmacol.Exp.Ther. 257 392 PMID: 2019998
Hargreaves et al (1992) L-689,660, a novel cholinomimetic with functional selectivity for M1 and M3 muscarinic receptors. Br.J.Pharmacol. 107 494 PMID: 1422595
If you know of a relevant reference for Cevimeline hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Cevimeline hydrochloride, Cevimeline hydrochloride supplier, AF102B, SNI2011, selective, M1, muscarinic, cholinergic, receptors, acetylcholine, Ach, agonists, AF, 102B, SNI, 2011, Receptors, 3689, Tocris Bioscience
Citations for Cevimeline hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for Cevimeline hydrochloride. Do you know of a great paper that uses Cevimeline hydrochloride from Tocris? Please let us know.
Reviews for Cevimeline hydrochloride
There are currently no reviews for this product. Be the first to review Cevimeline hydrochloride and earn rewards!
Have you used Cevimeline hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.